» Articles » PMID: 11343046

Clinical Outcome After Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

Overview
Journal J Pediatr
Specialty Pediatrics
Date 2001 May 9
PMID 11343046
Citations 134
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the clinical consequences of acquiring Pseudomonas aeruginosa infection during early childhood in children with cystic fibrosis (CF).

Design: Prospective, observational cohort study of 56 children with CF identified by newborn screening during 1990-92. Each child underwent an annual bronchial lavage during the first 2 to 3 years of life. Clinical outcome was determined at 7 years of age.

Results: P aeruginosa infection was diagnosed in 24 (43%) cohort subjects. Four children died before 7 years of age, all of whom had been infected with a multi-resistant, mucoid strain of P aeruginosa (P =.04). In survivors, P aeruginosa infection was associated with significantly increased morbidity as measured by lower National Institutes of Health scores, greater variability in lung function, increased time in the hospital, and higher rates of recombinant human deoxyribonuclease therapy (P <.01). In this young CF cohort, best forced expiratory volume in 1 second was an insensitive measure of increased morbidity.

Conclusions: Acquisition of P aeruginosa was common by 7 years of age in this CF birth cohort and was associated with increased morbidity and mortality. An improved disease severity score would improve the evaluation and study of early CF lung disease.

Citing Articles

superinfection drives Pf phage transmission within airway infections in patients with cystic fibrosis.

Pourtois J, Haddock N, Gupta A, Khosravi A, Martinez H, Schmidt A bioRxiv. 2025; .

PMID: 39868244 PMC: 11761399. DOI: 10.1101/2025.01.14.632786.


Antimicrobial peptide glatiramer acetate targets Pseudomonas aeruginosa lipopolysaccharides to breach membranes without altering lipopolysaccharide modification.

Murphy R, Pizzato J, Cuthbertson L, Sabnis A, Edwards A, Nolan L NPJ Antimicrob Resist. 2025; 2(1):4.

PMID: 39843948 PMC: 11702655. DOI: 10.1038/s44259-024-00022-x.


Antibiotic treatment of bacterial lung infections in cystic fibrosis.

Taccetti G, Terlizzi V, Campana S, Dolce D, Ravenni N, Fevola C Eur J Pediatr. 2024; 184(1):82.

PMID: 39672981 PMC: 11645307. DOI: 10.1007/s00431-024-05905-9.


Common regulatory mutation increases single-cell survival to antibiotic exposures in .

Ritz D, Deng Y, Schultz D bioRxiv. 2024; .

PMID: 39345531 PMC: 11430049. DOI: 10.1101/2024.09.20.614194.


The lysogenic filamentous bacteriophage phage Pf slows mucociliary transport.

Burgener E, Cai P, Kratochvil M, Rojas-Hernandez L, Joo N, Gupta A PNAS Nexus. 2024; 3(9):pgae390.

PMID: 39301510 PMC: 11412248. DOI: 10.1093/pnasnexus/pgae390.